Including added sugars on food labels — as proposed by the FDA to be required by 2021 — could prevent roughly 600,000 cases of diabetes and 355,000 cases of cardiovascular disease by 2037. (Circulation)
In related news, the FDA is allowing the low-cal sweetener allulose to be excluded from sugar counts on nutrition labels. “The latest data suggests that allulose is different from other sugars in that it is not metabolized by the human body in the same way as table sugar. It has fewer calories, produces only negligible increases in blood glucose or insulin levels, and does not promote dental decay,” the agency said.
The investigational drug atrasentan, a selective endothelin receptor antagonist, reduced risk for a composite of renal events in patients with chronic kidney disease and type 2 diabetes in the phase III SONAR trial. (The Lancet)
Once-daily combination estradiol and progesterone (1 mg/100 mg, Bijuva) hit the market this week for vasomotor symptoms of menopause, TherapeuticsMD announced.